285 related articles for article (PubMed ID: 7706911)
1. Platelet aggregation at high shear is impaired in patients with congenital defects of platelet secretion and is corrected by DDAVP: correlation with the bleeding time.
Cattaneo M; Pareti FI; Zighetti M; Lecchi A; Lombardi R; Mannucci PM
J Lab Clin Med; 1995 Apr; 125(4):540-7. PubMed ID: 7706911
[TBL] [Abstract][Full Text] [Related]
2. Role of ADP in platelet aggregation at high shear: studies in a patient with congenital defect of platelet responses to ADP.
Cattaneo M; Zighetti ML; Lombardi R; Mannucci PM
Br J Haematol; 1994 Dec; 88(4):826-9. PubMed ID: 7819105
[TBL] [Abstract][Full Text] [Related]
3. [Utility of desmopressin in 4 cases of thrombocytopathies associated with giant platelets].
Martínez-Murillo C; Quintana-González S; Ambriz-Fernández R; Arzate-Hernández G; Gutiérrez-Romero M; Gaminio-Gómez E
Rev Invest Clin; 1997; 49(4):281-6. PubMed ID: 9707993
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of platelet dysfunction and response to DDAVP in patients with congenital platelet function defects. A double-blind placebo-controlled trial.
Rao AK; Ghosh S; Sun L; Yang X; Disa J; Pickens P; Polansky M
Thromb Haemost; 1995 Oct; 74(4):1071-8. PubMed ID: 8560416
[TBL] [Abstract][Full Text] [Related]
5. Shear-induced platelet aggregation is potentiated by desmopressin and inhibited by ticlopidine.
Cattaneo M; Lombardi R; Bettega D; Lecchi A; Mannucci PM
Arterioscler Thromb; 1993 Mar; 13(3):393-7. PubMed ID: 8443143
[TBL] [Abstract][Full Text] [Related]
6. Shortening of bleeding time by 1-deamino-8-arginine vasopressin (DDAVP) in the absence of platelet von Willebrand factor in Gray platelet syndrome.
Pfueller SL; Howard MA; White JG; Menon C; Berry EW
Thromb Haemost; 1987 Dec; 58(4):1060-3. PubMed ID: 3502198
[TBL] [Abstract][Full Text] [Related]
7. [Shortening of acetylsalicylic acid-prolonged bleeding time by means of desmopressin].
Beck KH; Bleckmann U; Mohr P; Kretschmer V; Huss B
Beitr Infusionsther Transfusionsmed; 1994; 32():437-9. PubMed ID: 9480140
[TBL] [Abstract][Full Text] [Related]
8. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo effects of desmopressin on platelet function.
Balduini CL; Noris P; Belletti S; Spedini P; Gamba G
Haematologica; 1999 Oct; 84(10):891-6. PubMed ID: 10509036
[TBL] [Abstract][Full Text] [Related]
10. Uremic plasma after infusion of desmopressin (DDAVP) improves the interaction of normal platelets with vessel subendothelium.
Escolar G; Cases A; Monteagudo J; Garrido M; Lopez J; Ordinas A; Revert L; Castillo R
J Lab Clin Med; 1989 Jul; 114(1):36-42. PubMed ID: 2738447
[TBL] [Abstract][Full Text] [Related]
11. Laboratory response to intranasal desmopressin in women with menorrhagia and platelet dysfunction.
Rose SS; Faiz A; Miller CH; Saidi P; Philipp CS
Haemophilia; 2008 May; 14(3):571-8. PubMed ID: 18312366
[TBL] [Abstract][Full Text] [Related]
12. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
13. Low shear stress can initiate von Willebrand factor-dependent platelet aggregation in patients with type IIB and platelet-type von Willebrand disease.
Murata M; Fukuyama M; Satoh K; Fujimura Y; Yoshioka A; Takahashi H; Handa M; Kawai Y; Watanabe K; Ikeda Y
J Clin Invest; 1993 Sep; 92(3):1555-8. PubMed ID: 8376606
[TBL] [Abstract][Full Text] [Related]
14. Lack of effect of 1-desamino-8-D-arginine vasopressin on direct adhesion of platelets to collagen.
Ghosh S; Rao AK
Thromb Res; 1993 Jun; 70(5):417-22. PubMed ID: 7690994
[TBL] [Abstract][Full Text] [Related]
15. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
[TBL] [Abstract][Full Text] [Related]
16. The von Willebrand factor antagonist (GPG-290) prevents coronary thrombosis without prolongation of bleeding time.
Wadanoli M; Sako D; Shaw GD; Schaub RG; Wang Q; Tchernychev B; Xu J; Porter TJ; Huang Q
Thromb Haemost; 2007 Aug; 98(2):397-405. PubMed ID: 17721623
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of platelet function with the PFA-100 system in patients with congenital defects of platelet secretion.
Cattaneo M; Lecchi A; Agati B; Lombardi R; Zighetti ML
Thromb Res; 1999 Nov; 96(3):213-7. PubMed ID: 10588464
[TBL] [Abstract][Full Text] [Related]
18. Specific inhibiting effects of Ilexonin A on von Willebrand factor-dependent platelet aggregation under high shear rate.
Li M; Wu WK; Liu L; Liao FL; Shinohara Y; Handa S; Goto S
Chin Med J (Engl); 2004 Feb; 117(2):241-6. PubMed ID: 14975210
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the abnormal platelet function in von Willebrand disease by the blood filtration test.
Pareti FI; Cattaneo M; Carpinelli L; Zighetti ML; Bressi C; Mannucci PM; Ruggeri ZM
Thromb Haemost; 1996 Sep; 76(3):460-8. PubMed ID: 8883287
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of desmopressin effects on haemostasis in children with congenital bleeding disorders.
Hanebutt FL; Rolf N; Loesel A; Kuhlisch E; Siegert G; Knoefler R
Haemophilia; 2008 May; 14(3):524-30. PubMed ID: 18284449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
